Vivera Pharmaceuticals
- Company typePrivate
- Founded2018
- HeadquartersNewport Beach, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Vivera Pharmaceuticals firmographics
Firmographics- Name
- Vivera Pharmaceuticals
- Legal name
- Vivera Pharmaceuticals, Inc.
- Website
- https://viverapharmaceuticals.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Vivera Pharmaceuticals industry classification
Industry- Product category
- Pharmaceuticals and Medical Devices
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where Vivera Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Newport Beach
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Vivera Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Products: Revenue from proprietary pharmaceutical products utilizing the TABMELT sublingual drug delivery technology, including neuroscience medications for psychiatric and fluency disorders.
- Medical Devices: Revenue from ZICOH dose-controlled medication dispensing devices and other medical devices under development.
- COVID-19 Testing Services: Revenue from providing COVID-19 testing solutions including RT-PCR, antigen, and antibody testing through concierge laboratory services.
- TABMELT Licensing: Global exclusivity to license the patented and patent-pending TABMELT sublingual drug delivery system for pharmaceutical use of therapeutic compounds.
- Personal Protective Equipment (PPE): Revenue from manufacturing and distribution of PPE including gloves and masks made in the USA for first responders and healthcare centers.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Vivera Pharmaceuticals product offering
Product offeringCore offering
Vivera Pharmaceuticals develops and commercializes proprietary pharmaceutical products using the patented TABMELT sublingual drug delivery system and manufactures patented medical devices including the ZICOH dose-controlled electronic prescription dispensing device and the MDZone portable telemedicine station. The company also provides COVID-19 diagnostic testing services and PPE, and licenses TABMELT technology globally to pharmaceutical manufacturers for use with therapeutic compounds.
Product overview
Vivera Pharmaceuticals is an innovative, science-driven biopharma and medtech company organized into multiple divisions (Technologies, Biosciences, Medical Devices, Advanced Diagnostics, Neurosciences, Medical Technologies) offering a portfolio of patented products and drug delivery systems. The core product portfolio centers on TABMELT (sublingual drug delivery technology), ZICOH (dose-controlled electronic prescription dispensing device), MDZone (portable telemedicine station), and Lab Port (diagnostic testing software). Vivera is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products, with a focus on addressing the opioid crisis through non-addictive pain management solutions and prescription drug abuse deterrence.
Differentiator
Problem solved
Functional benefit
Brands
- ZICOH: Intelligent, dose-controlled electronic prescription dispensing device designed to improve medication safety, compliance, and adherence. Part of a closed-loop medication management system.
- MDZone
- TABMELT
- Vivera Cares
- Lab Port
Products and services
- TABMELT Sublingual Drug Delivery System A patented and patent-pending sublingual drug delivery system that allows patients to dissolve tablets under the tongue, bypassing the GI tract and first-pass liver metabolism for more instantaneous and accurate absorption than oral drug delivery. Licensed globally to pharmaceutical manufacturers for use with therapeutic compounds.
- ZICOH Dose-Controlled Medication Delivery Device An intelligent, dose-controlled electronic prescription dispensing device with fingerprint authentication, real-time monitoring of patient usage and compliance, and a closed-loop medication management system that connects the prescription supply chain from manufacturers to patients. Designed to deter prescription drug abuse and address the opioid crisis.
- MDZone Portable Telemedicine Station A portable, HIPAA-compliant telemedicine station that allows patients to access healthcare professionals remotely. Customizable with features including facial recognition, temperature monitoring, and sanitization capabilities.
- Lab Port Diagnostic Testing Software An innovative software system designed to streamline the diagnostic testing process for patients and providers, featuring a user-friendly interface for capturing patient data prior to administering medical tests.
- Speech Fluency Evaluation and Feedback Device A U.S. patent-allowed device for continuous monitoring of a patient's speech to provide accurate assessment and feedback for patients who stutter. Collects condition information allowing clinicians to monitor therapeutic effects and adjust treatment plans.
- COVID-19 Concierge Testing and Vaccination Services Concierge COVID-19 testing and vaccine clinic services including RT-PCR, antigen, and antibody testing, delivered on-site to enterprise clients including healthcare providers, government, educational institutions, long-term care facilities, event venues, and businesses.
- Personal Protective Equipment (PPE) Manufactured gloves and masks made in the USA, distributed to first responders and healthcare centers for pandemic response.
Quantifiable outcome
- Reduced risk of addiction and overdose through dose-controlled medication delivery and prescription compliance monitoring
- +1 more outcomes
Companies that use Vivera Pharmaceuticals
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Vivera Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Vivera Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and core.
- Mazars USA LLPminorInternational audit firm engaged by Vivera to complete public audit for fiscal years 2019 and 2020, supporting the company's financial transparency and reporting requirements.
- Areum Bio LLCcoreChannel partnership with Areum Bio LLC, a diagnostic testing distributor, to expand the national distribution of Access Bio's CareStart COVID-19 Rapid Antigen Tests. Vivera leverages its extensive network of healthcare providers and organizations for distribution.
- Burkhan GroupcorePartnership between Vivera Pharmaceuticals and Burkhan Group for COVID-19 testing initiative in Southern California. Together the two companies are expanding access to rapid testing as area businesses develop back-to-work protocols, focusing on the film, television, hospitality, and travel sectors.
- Access Bio, Inc.coreAccess Bio, Inc. is a New Jersey-based diagnostic manufacturer focused on research, development, and production of diagnostics for infectious diseases. Partnered with Vivera and Areum Bio for CareStart COVID-19 Rapid Antigen Test distribution.
- Managed Health Care Associates, Inc. (MHA)coreMHA is the largest alternate site Group Purchasing Organization (GPO) in the country, encompassing Atlantic Health Partners (nation's largest vaccine buying group). Vivera sponsors MHA's Annual Business Summit and showcases Advanced Diagnostics offerings and products from Pharmaceutical and Medical Device divisions.
- Central City Community Health CenterminorPartnered with Central City Community Health Center (federally qualified non-profit health care center) for COVID-19 and vaccination clinics throughout Los Angeles and Orange County regions, serving medically underserved and low-income populations.
- Capitol Health ServicesminorPartnership with Capitol Health Services, the health services provider for California State capitol staff and lawmakers, to host dedicated vaccine clinics. Working with Sacramento County Public Health and EquiVax for monthly vaccine and testing events.
- University of California at Riverside (UCR)minorVivera is developing its relationship with UCR to evaluate the potential to develop and license additional targeted novel therapeutics for the Neurosciences Division. Working with Dr. Gerald A. Maguire on neuroscience research initiatives.
Scale indicators3 records
Recent moves12 records
Expansion highlights6 records
Vivera Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Aquestive Therapeutics: Aquestive Therapeutics specializes in sublingual and oral film drug delivery technologies, including treatments for CNS conditions. It is directly comparable to Vivera's TABMELT sublingual drug delivery system, competing in the same product category and therapeutic areas.
- IntelGenx Technologies: IntelGenx develops oral thin film and sublingual drug delivery platforms for pharmaceutical partners. It is a direct competitor to Vivera's TABMELT sublingual technology, addressing similar bioavailability and patient adherence use cases.
- BioDelivery Sciences International: BDSI developed abuse-deterrent opioid formulations and pain management products using proprietary drug delivery technology. Its overlap with Vivera's ZICOH abuse-deterrent platform and focus on non-addictive pain management makes it a direct peer.
- Collegium Pharmaceutical: Collegium Pharmaceutical focuses on responsible pain management with abuse-deterrent, extended-release opioid products. It competes directly with Vivera's ZICOH device and opioid deterrence thesis.
- Orexo: Orexo is a Swedish specialty pharmaceutical company developing improved sublingual and mucosal drug delivery formulations, particularly for opioid use disorder. It is directly comparable to Vivera's TABMELT platform and CNS focus.
Broad incumbents
- Teva Pharmaceutical Industries: Teva is a major global pharmaceutical company headquartered in Israel (where Vivera recently secured TABMELT patent protection) and has been identified as a potential TABMELT licensing partner. As a broad incumbent with overlapping generic and specialty pharma operations, it represents both a competitor and a key commercialization channel for Vivera's technology.
- Pfizer: Pfizer is a major global pharmaceutical manufacturer with extensive CNS, pain management, and drug delivery capabilities. As a broad incumbent with the scale to license or compete with TABMELT technology, it represents a relevant peer for partnership or competitive dynamics.
- Becton Dickinson (BD): BD is a global medical device and drug delivery leader with substantial pharmaceutical systems, injection, and dispensing device portfolios. It competes broadly with Vivera's ZICOH dose-controlled medication dispensing platform and other medical device offerings.
Emerging players
- Pear Therapeutics: Pear Therapeutics developed prescription digital therapeutics for CNS conditions including substance use disorder, overlapping with Vivera's MDZone telemedicine and ZICOH prescription management approach to behavioral and addiction treatment.
- Nemaura Medical: Nemaura Medical develops needle-free drug delivery and continuous diagnostic monitoring technologies. Its combination of drug delivery and connected diagnostics overlaps with Vivera's ZICOH dose-controlled delivery and Lab Port diagnostic software strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Vivera Pharmaceuticals social profiles
Digital presenceVivera Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vivera Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles19 records
Vivera Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vivera Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vivera Pharmaceuticals
What does Vivera Pharmaceuticals do?
Vivera Pharmaceuticals develops and commercializes proprietary pharmaceutical products using the patented TABMELT sublingual drug delivery system and manufactures patented medical devices including the ZICOH dose-controlled electronic prescription dispensing device and the MDZone portable telemedicine station. The company also provides COVID-19 diagnostic testing services and PPE, and licenses TABMELT technology globally to pharmaceutical manufacturers for use with therapeutic compounds.
Is Vivera Pharmaceuticals a public or private company?
Vivera Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vivera Pharmaceuticals founded?
Vivera Pharmaceuticals was founded in 2018. It employs 101 to 250 people.
Where is Vivera Pharmaceuticals based?
Vivera Pharmaceuticals is headquartered in Newport Beach, United States, in the North America region.
How does Vivera Pharmaceuticals make money?
Five revenue lines are on record. Pharmaceutical Products are the primary driver. The others are medical Devices, COVID-19 Testing Services, TABMELT Licensing and personal Protective Equipment (PPE).
Who are Vivera Pharmaceuticals's main competitors?
Direct peers on record are Aquestive Therapeutics, IntelGenx Technologies, BioDelivery Sciences International, Collegium Pharmaceutical and Orexo. Broad incumbents are Teva Pharmaceutical Industries, Pfizer and Becton Dickinson (BD). Emerging players are Pear Therapeutics and Nemaura Medical.
Does Vivera Pharmaceuticals have an API?
No public API is recorded for Vivera Pharmaceuticals.
What industry is Vivera Pharmaceuticals in?
Vivera Pharmaceuticals's product category is Pharmaceuticals and Medical Devices. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring. Its NAICS code is 325412 and its SIC code is 2834.